resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone857-315-5521
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/9/2019 (Estimated)
OptionableNot Optionable
resTORbio (NASDAQ:TORC) Frequently Asked Questions
What is resTORbio's stock symbol?
resTORbio trades on the NASDAQ under the ticker symbol "TORC."
How were resTORbio's earnings last quarter?
resTORbio, Inc. (NASDAQ:TORC) announced its quarterly earnings results on Monday, March, 18th. The company reported ($0.21) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.34) by $0.13. View resTORbio's Earnings History.
When is resTORbio's next earnings date?
What is the consensus analysts' recommendation for resTORbio?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for resTORbio in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for resTORbio.
Has resTORbio been receiving favorable news coverage?
Headlines about TORC stock have trended somewhat negative on Tuesday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. resTORbio earned a coverage optimism score of -1.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of resTORbio's key competitors?
Some companies that are related to resTORbio include Alder Biopharmaceuticals (ALDR), Kiniksa Pharmaceuticals (KNSA), Radius Health (RDUS), Advanz Pharma (CXRXF), Omeros (OMER), Athenex (ATNX), Innovus Pharmaceuticals (INNV), Principia Biopharma (PRNB), Y-mAbs Therapeutics (YMAB), ANI Pharmaceuticals (ANIP), Eidos Therapeutics (EIDX), Rocket Pharmaceuticals (RCKT), Cara Therapeutics (CARA), CymaBay Therapeutics (CBAY) and Revance Therapeutics (RVNC).
What other stocks do shareholders of resTORbio own?
Who are resTORbio's key executives?
resTORbio's management team includes the folowing people:
- Mr. Chen Schor, Co-Founder, Pres, CEO & Director (Age 47)
- Dr. Joan Mannick M.D., Co-Founder & Chief Medical Officer (Age 60)
- Mr. John J. McCabe CPA, CPA, VP of Fin. (Age 51)
- Ms. Jennifer Robinson, Sr. Director of Investor Relations & Corp. Communication
- Dr. Abdellah Sentissi Ph.D., Head of CMC & Pharmaceutical Devel. (Age 69)
When did resTORbio IPO?
(TORC) raised $86 million in an IPO on Friday, January 26th 2018. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Leerink Partners and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are resTORbio's major shareholders?
resTORbio's stock is owned by many different of retail and institutional investors. Top institutional investors include Jennison Associates LLC (7.63%), BlackRock Inc. (2.86%), Segantii Capital Management Ltd (2.64%), Artal Group S.A. (1.43%), Deltec Asset Management LLC (0.94%) and Geode Capital Management LLC (0.31%). Company insiders that own resTORbio stock include Chen Schor, Orbimed Advisors Llc and Puretech Health Llc. View Institutional Ownership Trends for resTORbio.
Which major investors are selling resTORbio stock?
TORC stock was sold by a variety of institutional investors in the last quarter, including Deltec Asset Management LLC, Artal Group S.A., Jennison Associates LLC and Northern Trust Corp. View Insider Buying and Selling for resTORbio.
Which major investors are buying resTORbio stock?
TORC stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Segantii Capital Management Ltd, Geode Capital Management LLC, Geode Capital Management LLC, Bank of America Corp DE and Bank of New York Mellon Corp. Company insiders that have bought resTORbio stock in the last two years include Chen Schor, Orbimed Advisors Llc and Puretech Health Llc. View Insider Buying and Selling for resTORbio.
How do I buy shares of resTORbio?
Shares of TORC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is resTORbio's stock price today?
One share of TORC stock can currently be purchased for approximately $6.49.
How big of a company is resTORbio?
resTORbio has a market capitalization of $182.08 million. The company earns $-37,610,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis.
What is resTORbio's official website?
How can I contact resTORbio?
resTORbio's mailing address is 500 BOYLSTON STREET 12TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-315-5521.
MarketBeat Community Rating for resTORbio (NASDAQ TORC)
MarketBeat's community ratings are surveys of what our community members think about resTORbio and other stocks. Vote "Outperform" if you believe TORC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TORC will underperform the S&P 500 over the long term. You may vote once every thirty days.
